Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem-Cell Therapy NurOwn to Treat ALS – ALS News Today
ALS News Today |
Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem–Cell Therapy NurOwn to Treat ALS
ALS News Today NurOwn was developed by Tel Aviv University professors Dani Offen and the late Eldad Melamed. NurOwn builds on research developing mesenchymal stem cells (MSCs) as a treatment for human diseases. MSCs are multipotent precursor cells that exist in … |
ALS News Today |
Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem–Cell Therapy NurOwn to Treat ALS
ALS News Today NurOwn was developed by Tel Aviv University professors Dani Offen and the late Eldad Melamed. NurOwn builds on research developing mesenchymal stem cells (MSCs) as a treatment for human diseases. MSCs are multipotent precursor cells that exist in … |
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog) |
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … French Biotech Raises Over €22M to Launch a Gene Therapy to Restore SightLabiotech.eu (blog) |
|
CRISPR crew’s lab test spotlights lead program in sickle cell disease, beta-thalassemia
Endpoints News CRISPR/Cas9 tech is still at a very early stage of development. But one of the top biotechs looking to make a breakthrough in the clinic got a chance today to explain why one of its preclinical studies helps demonstrate gene editing’s promise in … European Hematology Association: Treating Sickle Cell Disease …PR Newswire (press release) |
|
Sarepta Signs Gene Therapy R&D Deal for DMD
Drug Discovery & Development Genethon specializes in a micro-dystrophin gene therapy approach that can target the majority of patients with DMD, according to the announcement. The organization has demonstrated proof-of-concept of their program through a robust gene expression in a … |
|
Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma
Cancer Network Immunotherapy Safely Treats Advanced Squamous Cell Carcinoma. News | June 23, 2017 | Skin Cancer (Nonmelanoma). By Mark L. Fuerst. A fully human anti–programmed death 1 (PD-1) monoclonal antibody is safe and effective for patients with … |
Labiotech.eu (blog) |
French Biotech Raises Over €22M to Launch a Gene Therapy to Restore Sight
Labiotech.eu (blog) Gensight Biologics has announced a capital increase that totals €22.5M and will support the launch of its gene therapy for blindness in Europe and the US. Gensight has decided to give an additional financial push to its lead candidate, GS010, a gene … |